Navigation Links
Cancer Vaccine Partnering Terms and Agreements

NEW YORK, May 16, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

Cancer Vaccine Partnering Terms and Agreements

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering dealsDisclosed headlines, upfronts, milestones and royalties by stage of developmentCancer vaccine partnering contract documentsTop cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2007

Analysis of cancer vaccine deal structure

Access to headline, upfront, milestone and royalty data

Access to over 200 cancer vaccine deal records

The leading cancer vaccine deals by value since 2007

Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How aresales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

Cancer Vaccine Partnering Agreements provides the reader with the following key benefits: In-depth understanding of cancer vaccine deal trends since 2007

Access to headline, upfront, milestone and royalty data

Acces to the structure of cancer vaccine agreements with numerous real life case studies

Comprehensive access to over 150 actual cancer vaccine deals entered into by the world's biopharma companies

Insight into the terms included in a cancer vaccine agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

TABLE OF CONTENTS Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer vaccine dealmaking

2.1. Introduction

2.2. Cancer vaccine partnering over the years

2.3. Bigpharma cancer vaccine dealmaking activity

2.4. Most active in cancer vaccine partnering

2.5. Cancer vaccine partnering by deal type

2.6. Cancer vaccine partnering by stage of development

2.7. Cancer vaccine partnering by cancer indication

2.8. Disclosed deal terms for cancer vaccine partnering

2.8.1 Cancer vaccine partnering headline values

2.8.2 Cancer vaccine deal upfront payments

2.8.3 Cancer vaccine deal milestone payments

2.8.4 Cancer vaccine royalty rates

2.9. The anatomy of cancer vaccine partnering

2.9. The anatomy of a cancer vaccine deal

2.9.a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012

2.9.b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007

Chapter 3 – Leading cancer vaccine deals

3.1. Introduction

3.2. Top cancer vaccine deals by value

Chapter 4 – Cancer vaccine dealmaking directory

4.1. Introduction

4.2. Company A-Z


Adamis Pharmaceuticals



Aduro BioTech



Agenus Bio


Alexis Biotech

Alligator Bioscience

Alnylam Pharmaceuticals

AnGes MG

Antigen Express


Argos Therapeutics

Ariad Pharmaceuticals

Arizona State University


Australian Centre for Vaccine Development

Avantogen Oncology

AVAX Technologies


Bavarian Nordic

Bayer Innovation

Baylor College

Baylor College of Medicine

Baylor Research Institute

Beijing Genomics Institute (BGI)

Bellicum Pharmaceuticals


Beth Israel Deaconess Medical Center



Bio-Matrix Scientific

BioAlliance Pharma


BioSante Pharmaceuticals



BN ImmunoTherapeutics

Brigham Young University

Bristol- Myers Squibb


BT Pharma

Cadila Pharmaceuticals

Cancer Research and Prevention Institute of Texas

Cancer Research Institute

Cancer Research Technology

Cancer Research UK

Cancer Research Wales

Cancer Treatment Centers of America

Cardiff University


Cedars-Sinai Medical Center

Cell Genesys

Celldex Therapeutics


CG Therapeutics

Champions Oncology

ChemRar High-Tech Center

City of Hope

Clinipace Worldwide

Cobra Biologics

Colby Pharmaceuticals



CureLab Oncology


Cyto Pulse Sciences


Daiichi Sankyo

Dalton Pharma Services

Dana-Farber Cancer Institute



Department of Defense


Dynavax Technologies

EMD Serono

Encorium Group

Entest BioMedical


Federal Ministry of Education and Research (BMBF)


Fraunhofer Institute for Cell Therapy and Immunology

Fred Hutchinson Cancer Research Center


Galena Biopharma


Generex Biotechnology

Genetic Immunity


Genomic Expression

German Cancer Research Center

German Ministry for Education and Research


Government of United Kingdom


Hawaii Biotechnology


HemispheRx Biopharma

Henderson Morley


Ichor Medical Systems

IDIS Pharma

Immatics Biotechnologies

Immune Design

ImmuneRegen BioSciences

ImmunoCellular Therapeutics




ImmunoVaccine Technologies



Inovio Biomedical

Inovio Pharmaceuticals

Institut Pasteur

IRX Therapeutics


Jaiva Technologies

Jantibody Therapeutics

Japan Vaccine


Johns Hopkins University

JSC Binnopharm

Juvaris BioTherapeutics


Karolinska Institute


Kirin Pharma

Kyowa Hakko Kirin


London Genetics

Ludwig Institute for Cancer Research

MabVax Therapeutics

Mary Crowley Cancer Research Center


Mayo Clinic

MD Anderson Cancer Center





Memorial Sloan Kettering Cancer Center

Merck & Co

Merck KGaA

Merck Serono

Merix Bioscience

Methodist Hospital Research Institute


Mount Sinai School of Medicine

Natco Pharmaceuticals

National Cancer Institute

National Cancer Research Center

National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Research Council Canada



Northwest Biotherapeutics

Norwegian Research Council




NYU Langone Medical Center

Ohio State University




Oncotherapy Science



Ono Pharmaceutical


Opsona Therapeutics

Oxford BioMedica

Oxford Immunotec

PDS Biotechnology

Pepscan Therapeutics






Pique Therapeutics

Pro-Cure Therapeutics

Progenitor Cell Therapy

Prostate Cancer Foundation (PCF)

PsiOxus Therapeutics

Public Health Service


Radboud University Nijmegen Medical Centre

Radient Pharmaceuticals


RXi Pharmaceuticals

Saint Savas Cancer Hospital


SBI Biotech


Scripps Research Institute

Serum Institute of India


Stellar Biotechnologies

Stellar Pharmaceuticals

Stemline Therapeutics

Symphony Dynamo

Systems Biology Worldwide

Takeda Pharmaceutical


Tasly Pharmaceuticals

Technomark Life Sciences

Teva Pharmaceuticals

The Regents of the University of California



Torrey Pines Institute for Molecular Studies


UK Government

UK Technology Strategy Board

University of Chicago

University of Connecticut

University of Copenhagen

University of Florida

University of Liege

University of North Carolina

University of Pennsylvania

University of Pennsylvania School of Veterinary Medicine

University of Pittsburgh

University of Queensland

University of Washington

Uppsala University



Vaxil BioTherapeutics


VGX Pharmaceuticals



VLST Corporation

Wistar Institute


Wuxi Apptec Laboratory Services


4.3. By stage of development




Phase I

Phase II

Phase III



4.4. By deal type

Asset purchase

Bigpharma outlicensing


Collaborative R&D


Contract service






Equity purchase



Joint venture




Material transfer






Technology transfer



4.5. By oncology therapy area


4.6. By related technology



Chapter 5 –Partnering resource center

5.1. Online partnering

5.2. Partnering events

5.3. Further reading on dealmaking


Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Therapy Reports

Order Form – Reports

Table of Figures Figure 1: Cancer vaccine partnering since 2007

Figure 2: Bigpharma – top 50 – cancer vaccine deals 2007 to 2013

Figure 3: Big pharma cancer vaccine deal frequency – 2007 to 2013

Figure 4: Active cancer vaccine dealmaking activity– 2007 to 2013

Figure 5: Cancer vaccine partnering by deal type since 2007

Figure 6: Cancer vaccine partnering by stage of development since 2007

Figure 7: Vaccine partnering by oncology target since 2007

Figure 8: Cancer vaccine deals with a headline value – by stage of development

Figure 9: Cancer vaccine deal headline value – median value by stage of development

Figure 10: Cancer vaccine deals with upfront payment values – by stage of development

Figure 11: Cancer vaccine deal upfront payment value – median value by stage of development

Figure 12: Cancer vaccine deals with milestone payment – by stage of development

Figure 13: Cancer vaccine deals with royalty rates-by stage of development

Figure 14: Components of the typical cancer vaccine deal structure

Figure 15: Top cancer vaccine deals by value since 2007

Figure 16: Online partnering resources

Figure 17: Forthcoming partnering events

Figure 18: Deal type definitions

To order this report:Biopharmaceutical Industry: Cancer Vaccine Partnering Terms and Agreements

Contact Clare:

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. RuiYi et Genor BioPharma collaborent au développement du RYI-008 en Chine, un nouveau traitement contre les maladies auto-immunes et le cancer
2. RuiYi and Genor BioPharma Collaborate on Development in China of RYI-008, a Novel Therapeutic for Autoimmune Diseases and Cancer
3. AbbVie to Present Data on Investigational Anti-Cancer Compounds at American Society of Clinical Oncology Annual Meeting
4. ASCO 2013: Boehringer Ingelheim to Present Data Across Multiple Cancers, Including Different Treatment Settings for Advanced NSCLC
5. Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting
6. Researchers Funded By The Pancreatic Cancer Action Network Leverage $9.15 Million Investment By The Organization Into $91 Million In Subsequent Pancreatic Cancer Research Funding
7. Cancer Diagnostic Testing World Markets
8. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
9. Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
10. Vermillion Supports First World Ovarian Cancer Day and Effort to Raise Awareness of the Need for Better Diagnosis and Treatment
11. Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
Post Your Comments:
(Date:11/30/2015)... 2015 Mexico Healthcare and Life Sciences Report ... 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million people. ... over 122 million people. --> It offers companies, investors, ... sciences insights into the second largest pharma and healthcare market in ...
(Date:11/29/2015)... Nov. 29, 2015   Royal Philips  (NYSE: PHG, ... solutions at the 2015 Radiological Society of North America ... McCormick Place in Chicago . Visitors ... the company,s broad portfolio of integrated Diagnostic Imaging, Clinical ... increase clinical performance, improve workflow and create a superior ...
(Date:11/27/2015)... Pays-Bas, November 27, 2015 ... traitement photodynamique au Bremachlorin contre le cancer avancé. ... consistant à combiner l,immunothérapie au traitement photodynamique au ... --> Une nouvelle approche consistant à ... le cancer avancé.    Clinical ...
Breaking Medicine Technology:
(Date:11/30/2015)... Grove, IL (PRWEB) , ... November 30, 2015 , ... ... for an emerging pharmaceutical company. Because it is so important to this key industry ... “Success Factors in your IND Filing” on December 4th at 11am EST. , Federal ...
(Date:11/30/2015)... Maryland (PRWEB) , ... November 30, 2015 , ... ... interactions could be of critical importance to the medical schools of the future. ... exhibited its healthcare suite at the 2015 ChangeMedEd conference in Chicago, organized by ...
(Date:11/30/2015)... , ... November 30, 2015 ... ... Inc. are pleased to announce their strategic partnership at the Radiological Society ... Transcription Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled ...
(Date:11/30/2015)... ... November 30, 2015 , ... Bayco Products, Inc today announced the introduction of three ... in a choice of three different colors; red ( NSP-1632 ), yellow ( NSP-1634 ) ... to 18 hours in constant-on mode, or 27 hours in blinking strobe mode using a ...
(Date:11/29/2015)... ... 30, 2015 , ... The Cyber Monday deal is a deep 40% or more discount on ... get gifts for the skin care lover in your circle. Each Christmas, Sublime Beauty ... year, the 3 serums are staples: Collagen, Retinol and Hyaluronic Serums. , Stocking stuffers like ...
Breaking Medicine News(10 mins):